Opinions expressed by Entrepreneur contributors are their own.
Key Takeaways Evolv co-founder Becca McCarthy saw a massive GLP-1 trend — and built a natural alternative to match it.
She believes appetite control doesn’t need a prescription, a needle, or a stigma.
Becca McCarthy says she’s always been good at recognizing when something is about to break into the mainstream. She has spent her career inside startups, helping turn early interest into real markets and building products before most people realize there’s demand for them.
That’s why, a few years ago, when she started hearing people in her network talking about GLP-1 drugs, she paid attention. GLP‑1 drugs such as Ozempic and Zepbound are among the fastest‑growing prescription medicines in the U.S., with total GLP‑1 sales worldwide estimated at around $50 billion.
But McCarthy was hearing about them long before they became cultural shorthand. Her otherwise healthy friends and family were injecting these drugs for weight loss and keeping it mostly to themselves. Using a medication designed for diabetes to manage appetite carried a stigma. It was considered cheating and ran counter to the wellness world’s insistence on clean eating, discipline, and willpower.
That’s when she saw an opportunity gap. “I thought, what if you could come up with a solve for this massive demand that’s building for efficacy from GLP-1 receptor activation without upsetting the diet and exercise police, then you have a massive solution.”
The answer eventually became Evolv, a natural, oral supplement designed to mimic the effects of GLP-1 without needles, prescriptions, synthetic hormones, or the judgment that surrounds pharmaceuticals.
Related: This Is How GLP-1 Drugs Are Forcing Restaurant Chains to Change Their Menus
A natural solution
... continue reading